B,inaticabtagene

Ying Wang1, Lulu Lv2, Yongping Song3

  • 1Leukemia Center, State Key Laboratory of Experimental Hematology, National Clinical Research Center of Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.

Blood advances
|December 3, 2024
PubMed
概括

在中国的成年R/R B-ALL患者中,Inaticabtagene autoleucel (Inati-cel) 显示了70.8%的整体缓解率. 这种新的CD19 CAR T细胞疗法显示出持久的反应和可管理的安全性,导致其获得批准.